Department of Blood and Marrow Transplant and Cellular Immunotherapy, Moffitt Cancer Center, Tampa, FL.
Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL.
Semin Hematol. 2024 Oct;61(5):290-296. doi: 10.1053/j.seminhematol.2024.08.005. Epub 2024 Aug 24.
Chimeric antigen receptor T-cell (CAR-T) has revolutionized the treatment of hematologic malignancies. There are several approvals in lymphomas, leukemias and myeloma. Randomized clinical trials have shown that CAR-T cell therapy improves survival over standard of care in diffuse large B-cell lymphoma (DLBCL) and multiple myeloma (MM), changing dramatically the current treatment paradigm. Current efforts are directed in improving outcomes in the frontline setting and confirmatory randomized trials are ongoing.
嵌合抗原受体 T 细胞（CAR-T）疗法彻底改变了血液系统恶性肿瘤的治疗方式。目前已经有多项批准用于淋巴瘤、白血病和骨髓瘤。随机临床试验表明，CAR-T 细胞疗法在弥漫性大 B 细胞淋巴瘤（DLBCL）和多发性骨髓瘤（MM）中的疗效优于标准治疗，极大地改变了当前的治疗模式。目前的努力方向是改善一线治疗的效果，正在进行确证性随机试验。
